Core Insights - Southbound funds reduced their holdings in Qiming Medical-B (02500.HK) by 121,500 shares on October 15, 2025, marking a decrease of 0.22% [1] - Over the past five trading days, there has been a cumulative net reduction of 437,000 shares, while in the last twenty trading days, the total net reduction reached 1,048,000 shares [1] - As of now, southbound funds hold 53,968,600 shares of Qiming Medical-B, which accounts for 12.23% of the company's total issued ordinary shares [1] Company Overview - Qiming Medical is primarily engaged in the research, development, production, and sales of biological heart valves, focusing on minimally invasive medical devices for treating heart valve diseases [2] - The company's product line includes devices for aortic, pulmonary, mitral, and tricuspid valve interventions, as well as systems for treating hypertrophic cardiomyopathy and renal artery denervation [2] - Key products include the VenusA-Valve system, VenusA-Plus system, VenusA-Pilot system, VenusP-Valve system, TMVR valve, TTVR valve, balloon for valve repair V8/TAV8, and TriGUARD3 cerebral embolic protection device [2]
启明医疗-B（02500.HK）：10月15日南向资金减持12.15万股